US2020085835A1PendingUtilityA1
Novel Formulation of Meloxicam
Est. expiryJun 9, 2034(~7.9 yrs left)· nominal 20-yr term from priority
Inventors:H. William Bosch
A61P 25/04A61P 29/00Y10T428/2982A61K 9/1617A61K 9/0053A61K 31/00A61K 9/14A61K 9/4858A61P 19/02A61K 9/1652A61K 9/1623A61K 31/5415A61K 9/145
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.
Claims
exact text as granted — not AI-modified1 . A unit dosage form of a pharmaceutical composition comprising 5 mg of meloxicam, wherein a single dose, upon oral administration to a population of healthy adults in the fasted state, provides a mean plasma AUC (0-∞) of 7500-20000 h*ng/ml.
2 .- 12 . (canceled)
13 . A unit dosage form comprising 10 mg of meloxicam, wherein a single dose, upon oral administration to a population of healthy adults in the fasted state, provides a mean plasma AUC (0-∞) of 16000-44000 h*ng/ml.
14 .- 30 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.